Why Halozyme’s Hypercon deal with Oruka could matter beyond one psoriasis antibody
Psoriasis biologics are getting longer acting. Halozyme and Oruka now face the harder test of making high-dose therapy practical.
Pharma & Biotech
Pharma & Biotech
Can UCB’s $2.2bn Candid Therapeutics deal reset the future of autoimmune therapy?
UCB is paying heavily for early autoimmune science. Candid tests whether T-cell engagers can move beyond oncology into immune reset.
Pharma & Biotech
Connect Biopharma advances rademikibart data as global competition grows in eczema biologics
Rademikibart Phase 3 eczema data will debut at AAD 2026. Discover what the trial could mean for IL-4 receptor biologics and global dermatology drug competition.
Pharma & Biotech
Can Enodia’s SEC61-targeting platform redefine druggability in secreted and membrane proteins?
Enodia Therapeutics raised €20.7M to advance AI-powered small molecules targeting SEC61 for selective protein degradation. Find out what this could change.